All for Joomla All for Webmasters

Anti tissue transglutaminase (tTG) antibodies could predict the development of celiac disease 5 years before the diagnosis?

Rate this item
(1 Vote)

Questions/answers on Anti tissue transglutaminase (tTG) antibodies could predict the development of celiac disease 5 years before the diagnosis

The cut-off identified with this study indicates the probability of a subject to be celiac at that time or to develop CD within 5 years. Nevertheless, it is necessary to evaluate the whole clinical picture: serological data instead must be correlated to the signs, symptoms and more generally to the patient's clinic to establish the best time to perform duodenal biopsy. Consequently, there are patients who are immediately sent for endoscopic examination while others are kept in follow up with repeated serological assays over time. The 170 CU cut off should be mainly used to understand how to manage low tTG values: therefore an asymptomatic patient with tTG value less than 170 CU and negative EMA can be monitored through tTG dosages over time, postponing the execution of the biopsy until tTG values increase or clinical conditions change, and in any case within one year from the first positive tTG determination. We have tried to identify an easy-to-use cut-off, whose application was not conditioned by the presence of symptoms, EMA positivity, sex or age of the patient: the work is not yet completed so when we will publish the results we will also evaluate the possibility to differentiate cut-off for pediatrics and adults, but at the moment the cut-off of 170 CU is suitable for all patients.

It is reported in literature that some genetic disease (such as Down Sdr and Turner Sdr) are associated with high risk of CD onset but also with the presence of provisional tTG positivity which values can increase or decrease without the presence of CD: some of these patients can develop CD but others can switch to negative. It is important to monitor those patients from both serological and clinical point of view. The same situation can occur in children but also in adults especially those affected from diabetes. Even in these cases it is important to follow up the patients and the decision to perform duodenal biopsy depends on patient’s clinical situation and its changes during time. Although rare, also tTG false positive results can occur, especially in presence of disease such as cirrhosis and Rheumatoid Arthritis but also in presence of interference substances in sera that could affect the performance of chemiluminescence assays.

Yes. During the first patient visit, the presence of indeterminate gastrointestinal symptoms leads the necessity to rule in or rule out several diseases; then the simultaneous evaluation of anti tTG and calprotectin can address clinicians towards CD or IBD or, if both tests are negative, towards IBS or functional disorders.

Testing for anti tTG IgG makes sense only in presence of IgA deficiency as recommended by international guidelines for diagnosis and management of CD. This is important especially due to the lack of specificity of IgG test in patients with normal levels of total IgA. In our region we had implemented the anti-tTG reflex test: when clinician orders for CD screening, total IgA is the first test performed in laboratory and, according to the result, IgA or IgG tests are implemented. Of course, CD patients with IgA deficiency should be followed up testing only tTG-IgG.

To answer this question, it is important to consider the clinical history and context of the patients; if they are adult patients, the results obtained have greater impact on patients managing course, especially for the one with positive EMA result, compared to the same result in children. It is also important to consider that to obtain a CD diagnosis we cannot consider serological test or duodenal biopsy or clinical features alone but we have to merge all the information: if they are adult patients with signs and symptoms suggestive for CD, it is necessary to perform the duodenal biopsy regardless from EMA results and even with low tTG value; if those patients are asymptomatic it is possible to postpone the duodenal biopsy and repeat tTG testing after 6 months and 1 year. If the positive results are confirmed or increased, it is necessary to perform the duodenal biopsy.

Previously ESPGHAN 2012 recommended to perform DGP autoantibodies in patients under 2 years old. From 2014 on, tTG reflex is the test for clinicians who need to screen patients for CD in our region: the algorithm of this test establishes to perform tTG and DGP for patients under 2 years old. New ESPGHAN 2020 confirm the main role for tTG as screening test even in children of all age also evidencing the low specificity for DGP tests; then we will consider asking a change of tTG reflex algorithm to remove the necessity to perform DGP in children under two years old.

Even if we found a suitable cut-off to avoid biopsy even in adult patients, this is not applied in our hospital for adults since the ESPGHAN guidelines are suitable only for children; moreover, it is recommended to perform endoscopy in adult patients to exclude the presence of other misdiagnosed diseases such as atrophic gastritis, helicobacter pylori infection or cancer. In children, on the other hand, the cut-off of 560 CU is applied for CD diagnosis protocol without duodenal biopsy, which is now applicable even in asymptomatic patients without searching for HLA genetic predisposition; in the event of a positive tTG <560 CU, duodenal biopsy is performed in the presence of signs / symptoms to confirm the diagnosis of CD; on the contrary in the absence of symptoms, for values <100 CU it is suggested follow up the children with repeated serological testing, for values between 100 and 560 CU the opportunity of the endoscopic examination is evaluated for each patient but in the majority of cases it is performed.

Additional Info

Read 2686 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection